Floatz logo

Samidorphan

Alcohol Use Disorder

Alkermes, Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Alcohol Use Disorder cohort.

Asset / SponsorPhaseRating
Cipralex
University of Texas Southwestern Medical Center
Phase 4BBB
Seroquel®
University of Cincinnati
Phase 4BBB
Naltrexone
VA Connecticut Healthcare System
Phase 4BBB
Topamax
University of California, San Francisco
Phase 4BB
Risperdal
Dartmouth-Hitchcock Medical Center
Phase 4BB

View all 28 →

Same molecule, other indications

Samidorphan is also rated in:

bipolar I disorderDormant
B
Indicative ·
62 / 100
View asset →
schizophreniaDormant
B
Indicative ·
56 / 100
View asset →
bipolar disorderDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →